0.1703
Medicus Pharma Ltd Aktie (MDCX) Neueste Nachrichten
Medicus Pharma (MDCX) grants COO 735K shares and options - Stock Titan
Medicus Pharma (NASDAQ: MDCX) awards stock and options to its chief medical officer - Stock Titan
Medicus Pharma (MDCX) hands CSO 588K shares and 100K options - Stock Titan
Medicus Pharma (MDCX) CEO adds millions of shares and options in 2026 grant - Stock Titan
CFO adds Medicus Pharma (MDCX) stock and options - Stock Titan
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs - Proactive financial news
Medicus Pharma Prioritises CD228V Oncology Programme in Development Strategy - Yahoo Finance
Medicus Pharma shifts focus to precision oncology with CD228V - Investing.com
Medicus Pharma shifts focus to precision oncology with CD228V By Investing.com - Investing.com UK
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - Yahoo Finance
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medi - ACCESS Newswire
Price to sales forward of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Medicus Pharma Ltd. Common Stock (NASDAQ: MDCX) Stock Price, News & Analysis - Kalkine
Pfizer hands former Seagen ADC to Medicus in USD 1b-plus deal - AllSci
MDCX Stock Price, Quote & Chart - ChartMill
Pfizer Licenses Discontinued Cancer Drug to Medicus Pharma in Deal Valued Over $1 Billion - finance.biggo.com
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion - Benzinga
Medicus Pharma Secures Global Rights to Pfizer’s CD228V with $12M Initial Payment and $15M Commitment - Kalkine Media
$Medicus Pharma (MDCX.US)$ - Moomoo
Medicus Pharma inks deal with Pfizer to advance clinical-stage ADC - The Pharma Letter
Pfizer, Medicus ink licensing deal worth up to $1B (PFE:NYSE) - Seeking Alpha
Medicus Pharma Signs Potential $1B Deal to License Pfizer’s Cancer Drug CD228V - Minichart
Medicus Pharma (MDCX) 10K Form and Latest SEC Filings 2026 - MarketBeat
Medicus Pharma Ltd. Submits to the FDA Phase 2 IND Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin - TMX Newsfile
Medicus Pharma Warrant (MDCXW) Holds Steady at $0.33 as Trading Range TightensRVOL Breakout - vinanet.vn
Medicus Pharma Ltd. Warrant (MDCXW) Holds at $0.33 as Tight Trading Range PersistsVolume Gap - siam.in
MDCX Should I Buy - Intellectia AI
Medicus (MDCX) Update: Slides 0.15% to $0.27 in the Latest Reading; Range Check - vinanet.vn
Medicus (MDCXW) Session: Ends a Quiet Session at $0.33 for the Current Session; Range Check: the Current Price Sits Inside the Supplied Technical Range in the Available RecordStock News - vinanet.vn
Medicus (MDCXW) Shares: Records a Muted Move to $0.33 in the Latest Session; Price Setup: Price Remains Between $0.31 Support and $0.35 Resistance in the Current UpdateCall Spread Alert - vinanet.vn
Medicus (MDCX) Quarterly Figures: The EPS Result Is Below Expectation in the Available Record; The Market Price Advances 1.15%Earnings Call Highlights - vinanet.vn
A. G. P. Maintains Medicus Pharma(MDCX.US) With Buy Rating, Cuts Target Price to $0.9 - Moomoo
Medicus Pharma on Bloomberg World - Coldwater Daily Reporter
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - dailyrecord.com
Top Medicus Pharma (MDCXW) Competitors 2026 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Market movers: Cisco, Cerebras, Medicus Pharma, Ideal Power... - Proactive financial news
Medicus Pharma advances clinical programs and r... - Pluang
Medicus Pharma advances pipeline during Q2 with key milestones - Yahoo Finance
Medicus Pharma Q2 loss widens to $11.7M, misses EPS estimate - scanx.trade
Medicus Pharma Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Corsicana Daily Sun
Medicus Pharma Ltd. Q2 2026: Net loss $(11.62M), EPS $(0.21) — 10-Q Summary - TradingView
Medicus Pharma (MDCX) widens loss as it raises $32M and adds secured notes - Stock Titan
Enterprise value to EBITDA forward of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Medicus Pharma (MDCX) Climbs 8.08% to $0.35 as Buying Interest BuildsHedge Fund Favorites - vinanet.vn
This 1 Stock Has Potential To Change Lives Maneskin (sRqAItrCwb) - Mshale
Price to book forward of Medicus Pharma Ltd. – NASDAQ:MDCX - TradingView
Price to earnings forward of Medicus Pharma Ltd. – NASDAQ:MDCX - TradingView
Medicus Pharma Ltd expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Medicus Pharma Ltd. Revenue Breakdown – BOATS:MDCXW - TradingView
Medicus Pharma names Faisal Mehmud CEO of UK subsidiary Antev - Investing.com
Medicus Pharma names Faisal Mehmud CEO of UK subsidiary Antev By Investing.com - Investing.com Nigeria
Medicus Pharma Names Dr. Faisal Mehmud CEO of UK Subsidiary Antev - citybiz
Medicus Pharma Appoints New CEO to Drive Development - Intellectia AI
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom - The Manila Times
Medicus Pharma targets Gorlin Syndrome with SkinJectICYMI - Proactive financial news
Small cap wrap: Medicus Pharma, Tiziana Life Sciences, Namibia Critical Metals... - Proactive financial news
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix - Yahoo! Finance Canada
Medicus Pharma receives UAE approval for endometriosis study By Investing.com - Investing.com Nigeria
Medicus Pharma Secures IND Authorization for Teverelix® Study in UAE - Intellectia AI
Medicus Pharma Ltd. (MDCX) Q1 2026 Earnings: Larger-than-Expected Loss Reported, Stock Edges Higher - vinanet.vn
Enterprise value to EBITDA forward of Medicus Pharma Ltd. – BOATS:MDCX - TradingView
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):